Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | NCOR1 | O75376 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209824 | 0.85 | CLK4 (0.74) | HDAC1CLK4DYRK1ACYP3A4CYP1A2 | |
| SCHEMBL1065202 | 0.84 | HDAC3 (0.74) | HDAC1CLK4DYRK1AHDAC3NCOR1 | |
| SCHEMBL211587 | 0.80 | ALDH1A1 (0.69) | HDAC1HDAC3NCOR1HDAC2HDAC8 | |
| SCHEMBL211906 | 0.78 | HDAC1 (1.00) | HDAC1HDAC3NCOR1HDAC2HDAC8 | |
| SCHEMBL17618077 | 0.78 | RAB9A (0.58) | HDAC1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL15761769 | 0.78 | RAB9A (0.62) | USP2ALDH1A1MAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL13188241 | 0.77 | DYRK1A (0.57) | CLK4DYRK1AHDAC3NCOR1HDAC2 | |
| SCHEMBL16264679 | 0.75 | ALDH1A1 (0.62) | HDAC1HDAC8HDAC6CYP3A4CYP1A2 | |
| SCHEMBL2345607 | 0.74 | CYP19A1 (0.74) | CYP19A1CYP11B1CYP11B2ABL1BCR | |
| SCHEMBL15761765 | 0.74 | CXCR4 (0.66) | ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735319-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2017-05-03 | — | — | EP | disclosed |
| EP-1735319-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2017-05-03 | — | — | EP | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885CLK4 2550/4885DYRK1A 3424/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885CLK4 2700/4885DYRK1A 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.